Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA | PLP1 Tmod CAR-T
- Development stage
- Preclinical
- Lead developer
- A2 Biotherapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PSMA | PLP1 Tmod CAR-T is an autologous T-cell therapy developed by A2 Biotherapeutics for the treatment of prostate cancer. It utilizes the company's proprietary Tmod (T-cell module) platform, which incorporates a synthetic NOT gate logic system to enhance safety and specificity. The CAR-T cells are engineered with an activator receptor targeting Prostate-Specific Membrane Antigen (PSMA) and an inhibitory receptor targeting Proteolipid Protein 1 (PLP1). While PSMA is highly expressed in prostate cancer, it is also present in the central nervous system (CNS), specifically in human oligodendrocytes and Schwann cells. PLP1, an integral membrane protein of the myelin sheath, is co-expressed with PSMA in these CNS tissues. The Tmod system allows the CAR-T cells to potently kill PSMA-positive tumor cells while sparing healthy CNS tissues that co-express PLP1, thereby addressing the potential risk of on-target, off-tumor neurotoxicity.
- Other names
- PSMA | PLP1 Tmod
Beyond the preview
Go deeper on PSMA | PLP1 Tmod CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA | PLP1 Tmod CAR-T.